Ipamorelin
Also known as NNC 26-0161, Ipamorelin acetate
A synthetic growth hormone secretagogue. Never approved; its one published clinical trial, in postoperative ileus, did not show a benefit.
Ipamorelin is a short synthetic peptide, five residues long, that stimulates the release of growth hormone. It acts on the receptor for ghrelin, and it was developed by Novo Nordisk in the 1990s. It has not been approved as a medicine by FDA, and has no entry in the register of medicines EMA has assessed; no other regulator was checked. FDA reports that it has been marketed for weight loss, anti-ageing, inflammatory conditions, sleep and bodybuilding, increasingly by medical spas and wellness clinics. No human study has measured any of those uses.
What it is
FDA's 2024 briefing document describes ipamorelin as a pentapeptide, Aib-His-D-2-Nal-D-Phe-Lys-NH2, containing non-proteinogenic amino acids, including aminoisobutyric acid (Aib) and naphthylalanine (Nal). Two of its residues are D-amino acids, the mirror-image forms. No sequence written in the twenty standard one-letter codes can describe it, which is why none is shown on this page.
Where the evidence stands
The human evidence is thin and none of it is about the uses ipamorelin is promoted for online. One published study gave single intravenous infusions to healthy men and measured growth hormone in their blood. One published efficacy trial, a small phase 2 proof-of-concept study, gave it intravenously to hospital patients after bowel surgery to see whether their gut recovered sooner, and found no significant difference from placebo. A third study, from an anti-doping laboratory, gave it nasally to one volunteer to find its breakdown products in urine. A PubMed search on 6 October 2026 for ipamorelin or its code NNC 26-0161 returned 54 records; none is a human study measuring muscle, body fat, sleep, injury recovery, athletic performance or ageing.
A second phase 2 trial by the same sponsor, NCT01280344, enrolled 320 people after bowel surgery and was completed in May 2014. It has no results posted on the registry, and no publication of it was found for this page. FDA's briefing, citing a 2020 publication, says development of ipamorelin for postoperative ileus was reportedly discontinued because of the study's disappointing results. It does not say when, and the second trial began after the first had finished.
The rest of the literature is in animals. Studies in rats and swine show growth hormone release, faster longitudinal bone growth in adult female rats, and preserved muscle strength in rats given steroids. Ipamorelin also increased body fat in mice, the opposite of the weight-loss use FDA reports it is marketed for. Faster gut recovery after surgery in rats was the animal result the human efficacy trial set out to test, and that trial did not show a significant difference.
FDA and compounding
Ipamorelin is not approved by FDA. It was nominated for the list of bulk substances that pharmacies may use in compounding under section 503A, and FDA evaluated it for growth hormone deficiency and postoperative ileus. In its briefing for the October 2024 advisory committee, FDA proposed not adding it, and concluded that there are no data to support its effectiveness by the subcutaneous route the nominations proposed. At the advisory committee meeting of 29 October 2024, asked whether to place it on the list, the committee voted 0 yes, 12 no and 1 abstaining for ipamorelin (free base), and the same for ipamorelin acetate. Members who voted no agreed there was a lack of information supporting safety and efficacy for those uses.
For outsourcing facilities under section 503B, FDA's list of nominated substances, updated 21 March 2025, places ipamorelin acetate in Category 2, substances that raise significant safety risks, and FDA's page on those risks, current as of 22 April 2026, still does. That page also lists ipamorelin acetate among nominations withdrawn by their nominators. FDA's 503A list of nominated substances, updated 14 May 2026, does not include ipamorelin in any of its categories. The documents read for this page do not say whether FDA has made a final determination on the 503A question.
FDA's briefing also reports, citing a TGA scheduling decision of February 2016, that Australia's Advisory Committee on Medicines Scheduling added ipamorelin to the Poisons Standard among performance and image enhancing drugs for which possession without authority is illegal. That is FDA's second-hand account; the TGA document itself could not be opened for this page. FDA's page on those risks refers to a published study that identified serious adverse events, including death, after intravenous use.
What is not known
Whether ipamorelin has any clinical benefit in people is not known. Its only published efficacy trial was small and showed no significant difference from placebo, and the larger one has no published results. For injection under the skin, the route proposed for compounding, FDA found no pharmacokinetic, pharmacodynamic or effectiveness data. Whether its selectivity for growth hormone, seen in swine, holds in people has not been shown in a published study. What is inside a given product is a separate question: seized preparations have contained a modified analogue of ipamorelin.
Anti-doping
WADA's Prohibited List names ipamorelin under S2.2.4, growth hormone releasing factors, prohibited at all times; the list was read in a browser by a person on 11 October 2026, because WADA's site refuses automated clients (source). Earlier second-hand accounts agree. FDA's 2024 briefing document states that ipamorelin is on WADA's list of prohibited substances under section S2.4, citing the 2023 list, and, citing a 2015 study, that substances including ipamorelin have been detected in vials confiscated from athletes.
What the research shows
Each statement below is labelled with the strongest kind of study supporting it, and links to that study.
- Human randomised trialNo effect found / Low confidence
In a phase 2 trial in adults after bowel resection, intravenous ipamorelin did not significantly shorten recovery of gut function compared with placebo.
The Ipamorelin 201 trial randomised adults undergoing small or large bowel resection to intravenous ipamorelin 0.03 mg/kg or placebo, double blind, in hospital. Of 117 enrolled, 114 formed the safety and modified intention-to-treat populations. Median time to the first tolerated solid meal was 25.3 hours with ipamorelin and 32.6 hours with placebo (p = 0.15). The authors report no significant differences between ipamorelin and placebo in the key or secondary efficacy analyses.
Tested in humans under randomised, controlled conditions.
- A small proof-of-concept trial that, in its authors' words, enrolled patients with a broad range of underlying conditions.
- It tested intravenous use in hospital patients for postoperative ileus. It had no endpoint for muscle, fat, sleep, recovery from exercise or ageing.
- FDA reports a subgroup analysis in which patients having open laparotomy recovered bowel function sooner on ipamorelin, and that the authors urged caution because of the small sample size. A subgroup in a trial that missed its main endpoint is a hypothesis, not a finding.
- A second, larger phase 2 trial by the same sponsor, NCT01280344, enrolled 320 people and was completed in May 2014. It has no posted results, and no publication of it was found.
- The figures come from the published abstract only.
- Human case reportSupportive / Low confidence
In healthy men, a single intravenous infusion of ipamorelin produced a single, short pulse of growth hormone release at every dose tested.
A pharmacokinetic study gave ipamorelin as 15-minute infusions at five dose levels to healthy men, eight at each level. Growth hormone rose in a single episode that peaked at 0.67 hours and declined to negligible concentrations, at all doses. Ipamorelin's terminal half-life was 2 hours.
One or a few individual cases. Cannot show whether an effect is general.
- This is a hormone level, not an outcome. A rise in growth hormone after one infusion says nothing about muscle, fat, recovery or performance.
- The abstract describes no control group. FDA describes the study as randomised and placebo-controlled, with six men on ipamorelin and two on placebo at each dose level, but states that the placebo groups and the lowest dose group were not included in the analysis because their growth hormone levels were negligible. The growth hormone result is therefore not a comparison with placebo on either account.
- Single doses only, intravenously, in healthy men.
- Animal researchSupportive / Low confidence
In swine, ipamorelin released growth hormone without raising ACTH or cortisol beyond what GHRH did, even at high doses.
In the study that first described ipamorelin, its developer, Novo Nordisk, found in conscious swine that ipamorelin released growth hormone with potency similar to GHRP-6 and did not raise ACTH or cortisol to levels significantly different from those after GHRH, even at doses more than 200-fold above the dose that gave half the maximal growth hormone release. GHRP-6 and GHRP-2 raised both.
Observed in animals. Animal results frequently fail to replicate in humans.
- Swine and rat data. The selectivity has not been shown in a published human study.
- First author affiliated with Novo Nordisk, which developed ipamorelin.
- Animal researchSupportive / Low confidence
In mice, ipamorelin increased body fat rather than reducing it.
In growth hormone-deficient and growth hormone-intact mice, ipamorelin increased fat pad weights relative to body weight, and two weeks of ipamorelin or GHRP-6 increased relative body fat measured by DEXA in growth hormone-intact mice, along with serum leptin and food intake. Growth hormone itself did not increase fat. The authors conclude that growth hormone secretagogues increase body fat by mechanisms independent of growth hormone, which may include increased feeding.
Observed in animals. Animal results frequently fail to replicate in humans.
- Mice, not humans. No human study has measured body fat with ipamorelin.
- Animal researchSupportive / Low confidence
In adult female rats, ipamorelin increased the rate of longitudinal bone growth and body weight.
Over 15 days, ipamorelin increased the longitudinal growth rate of the tibia in a dose-dependent way, from 42 micrometres a day with vehicle to 44, 50 and 52 micrometres a day, with a pronounced, dose-dependent gain in body weight. It did not change total IGF-I or serum markers of bone formation and resorption.
Observed in animals. Animal results frequently fail to replicate in humans.
- Rats, not humans.
- First author affiliated with Novo Nordisk, which developed ipamorelin.
- Animal researchSupportive / Low confidence
In rats given glucocorticoids, adding ipamorelin counteracted the loss of muscle strength and bone formation.
Eight-month-old female rats received methylprednisolone, ipamorelin, or both, for three months. In rats given both, the maximum tetanic tension of the calf muscles was significantly higher, and the periosteal bone formation rate four-fold higher, than in rats given methylprednisolone alone.
Observed in animals. Animal results frequently fail to replicate in humans.
- Rats, not humans. This is a model of steroid-induced loss, not of exercise, injury or ageing.
- Animal researchSupportive / Low confidence
In rats after abdominal surgery, ipamorelin sped up gut transit; the human trial that followed did not show a significant effect.
In male rats subjected to laparotomy and intestinal manipulation, a single intravenous dose of ipamorelin shortened the time to the first bowel movement, and repeated dosing increased fecal output, food intake and body weight gain. The authors suggested ipamorelin might help patients with postoperative ileus. The phase 2 trial in people did not show a significant difference from placebo.
Observed in animals. Animal results frequently fail to replicate in humans.
- Rats, not humans. Included because it is the rodent result that the one published human efficacy trial set out to test.
Reported and theoretical risks
- Human RCTserious
Adverse events in the one published human trial, including deaths whose relation to the drug FDA calls unclear
The trial's abstract reports treatment-emergent adverse events in 87.5% on ipamorelin and 94.8% on placebo, and calls ipamorelin well tolerated. FDA, reviewing the published trial for its 2024 advisory committee, reports that hypokalaemia (12.5% against 3.4%), insomnia (10.7% against 5.2%) and hyperglycaemia at discharge (14.3% against 8.6%) were more frequent on ipamorelin, and that serious adverse events occurred in 17.9% on ipamorelin against 15.5% on placebo, with no statistical comparison reported. Two people on ipamorelin died; both had bowel resection for colon cancer and developed an anastomotic leak after surgery. FDA writes that it is unclear whether the deaths were related to ipamorelin, but that their occurrence, with the higher rates of hypokalaemia and hyperglycaemia, raises safety concerns about its use in compounding.
- Mechanismunknown
No long-term safety data, and none for the routes proposed for compounding
FDA states that it did not identify published repeat-dose toxicity or genotoxicity studies of ipamorelin, and that there are no safety data for it given by the subcutaneous route proposed in the compounding nominations. It also states that it has not identified safety information for ipamorelin acetate via certain other injectable routes, and that it lacks sufficient information to know whether the drug would cause harm by those routes. For the subcutaneous route proposed in the compounding nominations, FDA found no pharmacokinetic or pharmacodynamic information. FDA adds that compounded ipamorelin may pose a risk of immunogenicity for certain routes of administration, because of possible aggregation or peptide-related impurities.
- Mechanismtheoretical
Risks FDA expects by analogy with approved growth hormone products
FDA notes that the labels of approved recombinant growth hormone products warn of, among others, an increased risk of neoplasm, glucose intolerance and diabetes, intracranial hypertension, fluid retention and pancreatitis, and says it is concerned that similar potential risks will be associated with ipamorelin. It also notes a risk of QT prolongation with macimorelin, an approved growth hormone secretagogue. These are risks of other products, raised by analogy. None has been measured with ipamorelin.
- In-vitrounknown
Seized preparations have contained modified analogues of ipamorelin
Unknown pharmaceutical preparations seized by Danish customs were analysed by mass spectrometry and identified as analogues of growth hormone secretagogues, including ipamorelin, each carrying an extra glycine at the N-terminus. The study does not report how the preparations were labelled. No study has examined the safety of these modified molecules.
Regulatory status
Status differs by country and changes over time. Each entry is dated and sourced.
USFDAnot approved
FDA states that neither ipamorelin nor ipamorelin acetate is a component of an FDA-approved drug, and that no USP or NF monograph exists for either. In its briefing for the October 2024 Pharmacy Compounding Advisory Committee, FDA proposed not adding either to the 503A Bulks List of substances pharmacists may compound with; the document says FDA will not issue a final determination until the advisory committee input and all reviews are complete.
As of 29 October 2024. Source
USFDAnot approved
FDA's page on bulk drug substances that may present significant safety risks, current as of 22 April 2026, lists ipamorelin acetate in Category 2 under the interim policy for outsourcing facilities (section 503B). Category 2 is a compounding category for substances that may present significant safety risks, not an approval decision. The same page lists it among substances whose nominations were withdrawn by the nominators, noting that it remains in 503B Category 2.
As of 22 April 2026. Source
EUEMAnot approved
Ipamorelin has no entry in the register of medicines EMA has assessed, in the copy generated on 2 October 2026. That register covers medicines assessed centrally by EMA, not authorisations granted by a single member state's national agency.
As of 2 October 2026. Source
internationalWADAbanned in sport
Named in WADA's Prohibited List under S2.2.4, growth hormone releasing factors, among "growth hormone secretagogues (GHS) and their mimetics". Section S2 is prohibited at all times, and its substances are non-Specified. The list was read in a browser by a person on 11 October 2026, because WADA's site refuses automated clients; the pasted text does not state the list's year.
As of 11 October 2026. Source
Research and analysis
Related peptides
- CJC-1295A synthetic analogue of growth hormone-releasing hormone
- TesamorelinA growth hormone-releasing hormone analogue approved in the US for one use: excess abdominal fat in adults with HIV and lipodystrophy
Sources
- 1. Beck DE et al. Prospective, randomized, controlled, proof-of-concept study of the Ghrelin mimetic ipamorelin for the management of postoperative ileus in bowel resection patients.. International Journal of Colorectal Disease. 2014. PubMed 25331030
- 2. Safety and Efficacy of Ipamorelin Compared to Placebo for the Recovery of Gastrointestinal Function. ClinicalTrials.gov. 2014. NCT01280344(open access)
- 3. FDA Briefing Document, Pharmacy Compounding Advisory Committee, October 29, 2024: Ipamorelin-Related Bulk Drug Substances (Ipamorelin (free base) and Ipamorelin Acetate). U.S. Food and Drug Administration. 2024. View source(open access)
- 4. Gobburu JV et al. Pharmacokinetic-pharmacodynamic modeling of ipamorelin, a growth hormone releasing peptide, in human volunteers.. Pharmaceutical Research. 1999. PubMed 10496658
- 5. Raun K et al. Ipamorelin, the first selective growth hormone secretagogue.. European Journal of Endocrinology. 1998. PubMed 9849822
- 6. Lall S et al. Growth hormone (GH)-independent stimulation of adiposity by GH secretagogues.. Biochemical and Biophysical Research Communications. 2001. PubMed 11162489
- 7. Johansen PB et al. Ipamorelin, a new growth-hormone-releasing peptide, induces longitudinal bone growth in rats.. Growth Hormone & IGF Research. 1999. PubMed 10373343
- 8. Andersen NB et al. The growth hormone secretagogue ipamorelin counteracts glucocorticoid-induced decrease in bone formation of adult rats.. Growth Hormone & IGF Research. 2001. PubMed 11735244
- 9. Venkova K et al. Efficacy of ipamorelin, a novel ghrelin mimetic, in a rodent model of postoperative ileus.. The Journal of Pharmacology and Experimental Therapeutics. 2009. PubMed 19289567
- 10. Certain Bulk Drug Substances for Use in Compounding that May Present Significant Safety Risks. U.S. Food and Drug Administration. 2026. View source(open access)
- 11. Gajda PM et al. Glycine-modified growth hormone secretagogues identified in seized doping material.. Drug Testing and Analysis. 2019. PubMed 30136411
- 12. Medicines output: medicines report (generated 2 October 2026). European Medicines Agency. 2026. View source(open access)
- 13. The Prohibited List, World Anti-Doping Agency. World Anti-Doping Agency. 2026. View source(open access)